Boding Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Boding Wang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Yiming Zhang
School of Computer Science, University of Nottingham Ningbo China, Ningbo, China
3 shared publications - Ying Weng
University of Nottingham Ningbo China
3 shared publications - Zhenzhu Li
Department of Neurosurgery, Ningbo No.2 Hospital, Ningbo, Zhejiang, 315000, China
3 shared publications - Chen Wanlu
Department of Neurosurgery, Ningbo No.2 Hospital, Ningbo, Zhejiang, 315000, China
2 shared publications - Chengtai Li
University of Nottingham Ningbo China
2 shared publications Hongcai Wang
Department of Neurosurgery, Li Huili Hospital, Ningbo Medical Center, Ningbo, China
2 shared publications
Latest Publications
- Open Access
- 29 August 2025
- Published by Springer Nature in Artificial Intelligence Review
- Vol. 58 (11) , 1-58
Applications of machine learning for computer-aided diagnosis of Parkinson’s disease: progress and benchmark case study
Machine learning (ML) has emerged as a vital tool for the diagnosis of Parkinson’s Disease (PD). This study presents a comprehensive review on the applications of ML for computer-aided diagnosis (CAD) of PD. We conducted a comprehensive review by searching articles published from 2010 till 2024. The risk of bias is assessed using the PROBAST checklist. Case studies are also provided. This review includes 117 articles with six categories: neuroimaging data (20.5%); voice data (40.2%); handwriting data (12.0%); gait data (14.5%); EEG data (8.5%); and other data (4.3%). According to the PROBAST checklist, only 28 articles (23.9%) have a low risk of bias. A benchmark case study is conducted for five different data modalities. We also discuss current limitations and future directions of applying ML to the diagnosis of PD. This review reduces the gap between Artificial Intelligence (AI) and PD medical professionals and provides helpful information for future research.
- 29 August 2025
- Published by Springer Nature in Artificial Intelligence Review
- Vol. 58 (11) , 1-58
Open AccessApplications of machine learning for computer-aided diagnosis of Parkinson’s disease: progress and benchmark case study
Machine learning (ML) has emerged as a vital tool for the diagnosis of Parkinson’s Disease (PD). This study presents a comprehensive review on the applications of ML for computer-aided diagnosis (CAD) of PD. We conducted a comprehensive review by searching articles published from 2010 till 2024. The risk of bias is assessed using the PROBAST checklist. Case studies are also provided. This review includes 117 articles with six categories: neuroimaging data (20.5%); voice data (40.2%); handwriting data (12.0%); gait data (14.5%); EEG data (8.5%); and other data (4.3%). According to the PROBAST checklist, only 28 articles (23.9%) have a low risk of bias. A benchmark case study is conducted for five different data modalities. We also discuss current limitations and future directions of applying ML to the diagnosis of PD. This review reduces the gap between Artificial Intelligence (AI) and PD medical professionals and provides helpful information for future research.
- Open Access
- 10 July 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (1) , 537-538
Application of the "Hand-as-Foot" teaching method in the complex cavernous part of the internal carotid artery
- 10 July 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (1) , 537-538
Open AccessApplication of the "Hand-as-Foot" teaching method in the complex cavernous part of the internal carotid artery
- Open Access
- 26 June 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (12) , 5293-5294
The application of the “Gesture” teaching model for the complex Kawase surgical approach
- 26 June 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (12) , 5293-5294
Open AccessThe application of the “Gesture” teaching model for the complex Kawase surgical approach
- 29 January 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-12
Schizandrin A attenuates early brain injury following subarachnoid hemorrhage through suppressing neuroinflammation
Background Early brain injury (EBI) is the vital factor in determining the outcome of subarachnoid hemorrhage (SAH). Schizandrin A (Sch A), the bioactive ingredient extracted from Schisandra chinensis, has been proved to exert beneficial effects in multiple human diseases. However, the effect of Sch A on SAH remains unknown. The current study was designed to explored role and mechanism of Sch A in the pathophysiological process of EBI following SAH. Method A total of 74 male C57BL/6 J mice were subjected to endovascular perforation to establish the SAH model. Different dosages of Sch A were administrated post-modeling. The post-modeling assessments included neurological test, brain water content, RT-PCR, immunofluorescence, Nissl staining. Oxygenated hemoglobin was introduced into microglia to establish a SAH model in vitro. Result Sch A significantly alleviated SAH-induced brain edema and neurological impairment. Moreover, application of Sch A remarkably inhibited SAH-induced neuroinflammation, evidenced by the decreased microglial activation and downregulated TNF-α, IL-1β and IL-6 and expression. Additionally, Sch A, both in vivo and in vitro, protected neurons against SAH-induced inflammatory injury. Mechanismly, administration of Sch A inhibited miR-155/NF-κB axis and attenuated neuroinflammation, as well as alleviating neuronal injury. Conclusion Our data suggested that Sch A could attenuated EBI following SAH via modulating neuroinflammation. The anti-inflammatory effect was exerted, at least partly through the miR-155/NF-κB axis, which may shed light on a possible therapeutic target for SAH. Graphical Abstract
- 29 January 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-12
Schizandrin A attenuates early brain injury following subarachnoid hemorrhage through suppressing neuroinflammation
Background Early brain injury (EBI) is the vital factor in determining the outcome of subarachnoid hemorrhage (SAH). Schizandrin A (Sch A), the bioactive ingredient extracted from Schisandra chinensis, has been proved to exert beneficial effects in multiple human diseases. However, the effect of Sch A on SAH remains unknown. The current study was designed to explored role and mechanism of Sch A in the pathophysiological process of EBI following SAH. Method A total of 74 male C57BL/6 J mice were subjected to endovascular perforation to establish the SAH model. Different dosages of Sch A were administrated post-modeling. The post-modeling assessments included neurological test, brain water content, RT-PCR, immunofluorescence, Nissl staining. Oxygenated hemoglobin was introduced into microglia to establish a SAH model in vitro. Result Sch A significantly alleviated SAH-induced brain edema and neurological impairment. Moreover, application of Sch A remarkably inhibited SAH-induced neuroinflammation, evidenced by the decreased microglial activation and downregulated TNF-α, IL-1β and IL-6 and expression. Additionally, Sch A, both in vivo and in vitro, protected neurons against SAH-induced inflammatory injury. Mechanismly, administration of Sch A inhibited miR-155/NF-κB axis and attenuated neuroinflammation, as well as alleviating neuronal injury. Conclusion Our data suggested that Sch A could attenuated EBI following SAH via modulating neuroinflammation. The anti-inflammatory effect was exerted, at least partly through the miR-155/NF-κB axis, which may shed light on a possible therapeutic target for SAH. Graphical Abstract
- Open Access
- 1 February 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (3) , 537
A Systematic Review of Application Progress on Machine Learning-Based Natural Language Processing in Breast Cancer over the Past 5 Years
Artificial intelligence (AI) has been steadily developing in the medical field in the past few years, and AI-based applications have advanced cancer diagnosis. Breast cancer has a massive amount of data in oncology. There has been a high level of research enthusiasm to apply AI techniques to assist in breast cancer diagnosis and improve doctors’ efficiency. However, the wise utilization of tedious breast cancer-related medical care is still challenging. Over the past few years, AI-based NLP applications have been increasingly proposed in breast cancer. In this systematic review, we conduct the review using preferred reporting items for systematic reviews and meta-analyses (PRISMA) and investigate the recent five years of literature in natural language processing (NLP)-based AI applications. This systematic review aims to uncover the recent trends in this area, close the research gap, and help doctors better understand the NLP application pipeline. We first conduct an initial literature search of 202 publications from Scopus, Web of Science, PubMed, Google Scholar, and the Association for Computational Linguistics (ACL) Anthology. Then, we screen the literature based on inclusion and exclusion criteria. Next, we categorize and analyze the advantages and disadvantages of the different machine learning models. We also discuss the current challenges, such as the lack of a public dataset. Furthermore, we suggest some promising future directions, including semi-supervised learning, active learning, and transfer learning.
- 1 February 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (3) , 537
Open AccessA Systematic Review of Application Progress on Machine Learning-Based Natural Language Processing in Breast Cancer over the Past 5 Years
Artificial intelligence (AI) has been steadily developing in the medical field in the past few years, and AI-based applications have advanced cancer diagnosis. Breast cancer has a massive amount of data in oncology. There has been a high level of research enthusiasm to apply AI techniques to assist in breast cancer diagnosis and improve doctors’ efficiency. However, the wise utilization of tedious breast cancer-related medical care is still challenging. Over the past few years, AI-based NLP applications have been increasingly proposed in breast cancer. In this systematic review, we conduct the review using preferred reporting items for systematic reviews and meta-analyses (PRISMA) and investigate the recent five years of literature in natural language processing (NLP)-based AI applications. This systematic review aims to uncover the recent trends in this area, close the research gap, and help doctors better understand the NLP application pipeline. We first conduct an initial literature search of 202 publications from Scopus, Web of Science, PubMed, Google Scholar, and the Association for Computational Linguistics (ACL) Anthology. Then, we screen the literature based on inclusion and exclusion criteria. Next, we categorize and analyze the advantages and disadvantages of the different machine learning models. We also discuss the current challenges, such as the lack of a public dataset. Furthermore, we suggest some promising future directions, including semi-supervised learning, active learning, and transfer learning.
- Open Access
- 12 January 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (2) , 286
Natural Language Processing Applications for Computer-Aided Diagnosis in Oncology
In the era of big data, text-based medical data, such as electronic health records (EHR) and electronic medical records (EMR), are growing rapidly. EHR and EMR are collected from patients to record their basic information, lab tests, vital signs, clinical notes, and reports. EHR and EMR contain the helpful information to assist oncologists in computer-aided diagnosis and decision making. However, it is time consuming for doctors to extract the valuable information they need and analyze the information from the EHR and EMR data. Recently, more and more research works have applied natural language processing (NLP) techniques, i.e., rule-based, machine learning-based, and deep learning-based techniques, on the EHR and EMR data for computer-aided diagnosis in oncology. The objective of this review is to narratively review the recent progress in the area of NLP applications for computer-aided diagnosis in oncology. Moreover, we intend to reduce the research gap between artificial intelligence (AI) experts and clinical specialists to design better NLP applications. We originally identified 295 articles from the three electronic databases: PubMed, Google Scholar, and ACL Anthology; then, we removed the duplicated papers and manually screened the irrelevant papers based on the content of the abstract; finally, we included a total of 23 articles after the screening process of the literature review. Furthermore, we provided an in-depth analysis and categorized these studies into seven cancer types: breast cancer, lung cancer, liver cancer, prostate cancer, pancreatic cancer, colorectal cancer, and brain tumors. Additionally, we identified the current limitations of NLP applications on supporting the clinical practices and we suggest some promising future research directions in this paper.
- 12 January 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (2) , 286
Open AccessNatural Language Processing Applications for Computer-Aided Diagnosis in Oncology
In the era of big data, text-based medical data, such as electronic health records (EHR) and electronic medical records (EMR), are growing rapidly. EHR and EMR are collected from patients to record their basic information, lab tests, vital signs, clinical notes, and reports. EHR and EMR contain the helpful information to assist oncologists in computer-aided diagnosis and decision making. However, it is time consuming for doctors to extract the valuable information they need and analyze the information from the EHR and EMR data. Recently, more and more research works have applied natural language processing (NLP) techniques, i.e., rule-based, machine learning-based, and deep learning-based techniques, on the EHR and EMR data for computer-aided diagnosis in oncology. The objective of this review is to narratively review the recent progress in the area of NLP applications for computer-aided diagnosis in oncology. Moreover, we intend to reduce the research gap between artificial intelligence (AI) experts and clinical specialists to design better NLP applications. We originally identified 295 articles from the three electronic databases: PubMed, Google Scholar, and ACL Anthology; then, we removed the duplicated papers and manually screened the irrelevant papers based on the content of the abstract; finally, we included a total of 23 articles after the screening process of the literature review. Furthermore, we provided an in-depth analysis and categorized these studies into seven cancer types: breast cancer, lung cancer, liver cancer, prostate cancer, pancreatic cancer, colorectal cancer, and brain tumors. Additionally, we identified the current limitations of NLP applications on supporting the clinical practices and we suggest some promising future research directions in this paper.
- 25 May 2021
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 14 (5) , 457-463
First-line contact aspiration versus first-line stent retriever for acute posterior circulation strokes: an updated meta-analysis
Background: Both stent retriever (SR) and contact aspiration (CA) are widely used as first-line strategies for acute posterior circulation strokes (PCS). However, it is still unclear how CA and SR compare as the first-line treatment of acute PCS. Several new studies have been published recently, so we aimed to perform an updated meta-analysis.Methods: The meta-analysis was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement. Random-effects models were performed to pool the outcomes and the value of I2was calculated to assess the heterogeneity.Results: Ten observational studies with 1189 patients were included, among whom 492 received first-line CA and 697 received first-line SR. The pooled results revealed that first-line CA could achieve a significantly higher proportion of modified Thrombolysis In Cerebral Infarction (mTICI) 2b/3 (OR 1.90, 95% CI 1.33 to 2.71, I2=0%), mTICI 3 (OR 1.95, 95% CI 1.15 to 3.31, I2=59.6%), first-pass effect (OR 2.91, 95% CI 1.51 to 5.58, I2=0%), lower incidence of new-territory embolic events (OR 0.20, 95% CI 0.05 to 0.83, I2=0%), and shorter procedure time (mean difference −29.4 min, 95% CI −46.8 to −12.0 min, I2=62.8%) compared with first-line SR. At 90-day follow-up, patients subjected to first-line CA showed a higher functional independence (modified Rankin Scale score 0–2; OR 1.38, 95% CI 1.01 to 1.87, I2=23.5%) and a lower mortality (OR 0.71, 95% CI 0.50 to 1.00, p=0.050, I2=0%) than those subjected to first-line SR.Conclusions: This meta-analysis suggests that the first-line CA strategy could achieve better recanalization and clinical outcomes for acute PCS than first-line SR. Limited by the quality of included studies, this conclusion should be drawn with caution.
- 25 May 2021
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 14 (5) , 457-463
First-line contact aspiration versus first-line stent retriever for acute posterior circulation strokes: an updated meta-analysis
Background: Both stent retriever (SR) and contact aspiration (CA) are widely used as first-line strategies for acute posterior circulation strokes (PCS). However, it is still unclear how CA and SR compare as the first-line treatment of acute PCS. Several new studies have been published recently, so we aimed to perform an updated meta-analysis.Methods: The meta-analysis was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement. Random-effects models were performed to pool the outcomes and the value of I2was calculated to assess the heterogeneity.Results: Ten observational studies with 1189 patients were included, among whom 492 received first-line CA and 697 received first-line SR. The pooled results revealed that first-line CA could achieve a significantly higher proportion of modified Thrombolysis In Cerebral Infarction (mTICI) 2b/3 (OR 1.90, 95% CI 1.33 to 2.71, I2=0%), mTICI 3 (OR 1.95, 95% CI 1.15 to 3.31, I2=59.6%), first-pass effect (OR 2.91, 95% CI 1.51 to 5.58, I2=0%), lower incidence of new-territory embolic events (OR 0.20, 95% CI 0.05 to 0.83, I2=0%), and shorter procedure time (mean difference −29.4 min, 95% CI −46.8 to −12.0 min, I2=62.8%) compared with first-line SR. At 90-day follow-up, patients subjected to first-line CA showed a higher functional independence (modified Rankin Scale score 0–2; OR 1.38, 95% CI 1.01 to 1.87, I2=23.5%) and a lower mortality (OR 0.71, 95% CI 0.50 to 1.00, p=0.050, I2=0%) than those subjected to first-line SR.Conclusions: This meta-analysis suggests that the first-line CA strategy could achieve better recanalization and clinical outcomes for acute PCS than first-line SR. Limited by the quality of included studies, this conclusion should be drawn with caution.
- Open Access
- 30 December 2020
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 14 (12) , 1368-1373
Long-term application of hydroxychloroquine could not prevent the infection of COVID-19
Introduction: Current pandemic of the coronavirus induced disease 2019 (COVID-19) presents an urgent issue to the world due to lack of vaccine and medication. Hydroxychloroquine (HCQ) has generated a lot of controversies whether it is effective in prevention and treatment of COVID-19. Current report presents a 63-year-old woman who has taken HCQ for many years but still infected by COVID-19. Case presentation: A patient with rheumatoid arthritis came to the clinic with fever and sore throat. The patient has been treated with 200 mg HCQ per day since 2016. Laboratory tests showed that the patient had lymphopenia, increased levels of high-sensitive C-reactive protein (hs-CRP) and serum Interleukin-6 (IL-6). Chest radiography showed that the patient had pneumonia. Throat swab test confirmed COVID-19 positive. On admission, she was treated with nebulized interferon alfa-2b, oral Lopinavir/Ritonavir, and ceftriaxone sodium for the COVID-19 in addition to HCQ. The patient stayed in hospital for 18 days, recovered from oxygen intake, and eventually discharged from hospital. Follow up investigation showed the patient developed antibody against COVID-19. Conclusions: Long-term application of HCQ could not prevent COVID-19 infection, but whether HCQ exerts benefit to alleviation of clinical symptoms and duration of hospital stays remains to be further investigated.
- 30 December 2020
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 14 (12) , 1368-1373
Open AccessLong-term application of hydroxychloroquine could not prevent the infection of COVID-19
Introduction: Current pandemic of the coronavirus induced disease 2019 (COVID-19) presents an urgent issue to the world due to lack of vaccine and medication. Hydroxychloroquine (HCQ) has generated a lot of controversies whether it is effective in prevention and treatment of COVID-19. Current report presents a 63-year-old woman who has taken HCQ for many years but still infected by COVID-19. Case presentation: A patient with rheumatoid arthritis came to the clinic with fever and sore throat. The patient has been treated with 200 mg HCQ per day since 2016. Laboratory tests showed that the patient had lymphopenia, increased levels of high-sensitive C-reactive protein (hs-CRP) and serum Interleukin-6 (IL-6). Chest radiography showed that the patient had pneumonia. Throat swab test confirmed COVID-19 positive. On admission, she was treated with nebulized interferon alfa-2b, oral Lopinavir/Ritonavir, and ceftriaxone sodium for the COVID-19 in addition to HCQ. The patient stayed in hospital for 18 days, recovered from oxygen intake, and eventually discharged from hospital. Follow up investigation showed the patient developed antibody against COVID-19. Conclusions: Long-term application of HCQ could not prevent COVID-19 infection, but whether HCQ exerts benefit to alleviation of clinical symptoms and duration of hospital stays remains to be further investigated.